• Hypertrophic Cardiomyopathy (HCM)
  • Eyecare
  • Urothelial Carcinoma
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

MHE State of the Industry survey: The shift to value-based care

MHE PublicationMHE December 2020
Volume 30
Issue 12

In this fifth part of a six-part series, data said respondents split on the effect of the pandemic on value-based care

Some see the COVID-19 pandemic as pushing American healthcare away from fee for service and into value-based care. The message from our State of the Industry survey is mixed. Almost half (46%) indicated that the pandemic had no effect on their organization’s relationship with value-based care and 9% said it had negative effect. On the other hand, 44% indicated some level of increase, including 5% who said it greatly increased value-based care.

Downside risk, which many see as essential to putting some cost-saving teeth into value-based care, still hasn’t taken hold, judging by our respondents. Two-thirds indicated that less than 25% of their value-based arrangements involved downside risk, and only 5% indicated that more than 50% of their value-based contracts involved downside risk."

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.